title: Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
authors.forename: Massimo
authors.initials: M
authors.lastname: Offidani
authors.forename: Monica
authors.initials: M
authors.lastname: Marconi
authors.forename: Laura
authors.initials: L
authors.lastname: Corvatta
authors.forename: Attilio
authors.initials: A
authors.lastname: Olivieri
authors.forename: Massimo
authors.initials: M
authors.lastname: Catarini
authors.forename: Pietro
authors.initials: P
authors.lastname: Leoni
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D016879:Salvage Therapy; D016019:Survival Analysis; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000139:chemically induced
chemical_list: D013792:Thalidomide; D008558:Melphalan